Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate

Authors

Trevor B Cabrera
Allison L Speer
Matthew R Greives
Donna A Goff
Neethu M Menon
Eric W Reynolds

Publication Date

10-1-2020

Journal

American Journal of Perinatology Reports

Abstract

We present a case of a neonate born with kaposiform hemangioendothelioma (KHE), complicated by Kasabach-Merritt phenomenon (KMP) and other serious conditions, who was successfully treated with sirolimus. In addition to complications from thrombocytopenia and fluid overload, during the course of therapy, our patient experienced supratherapeutic drug levels at the commonly accepted starting dose of sirolimus. Patients with KHE and KMP should be closely monitored for potential complications of both the initial disease and unexpected side effects of treatments.

Keywords

kaposiform hemangioendothelioma, Kasabach-Merritt phenomenon, sirolimus

Comments

PMID: 33214934